BlackRock’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-564,004
| Closed | -$1.88M | – | 5149 |
|
|
2019
Q4 | $1.88M | Sell |
564,004
-33,348
| -6% | -$106K | ﹤0.01% | 3813 |
|
|
2019
Q3 | $1.82M | Buy |
597,352
+52,456
| +10% | +$148K | ﹤0.01% | 3784 |
|
|
2019
Q2 | $1.3M | Sell |
544,896
-41,165
| -7% | -$123K | ﹤0.01% | 3932 |
|
|
2019
Q1 | $2.2M | Sell |
586,061
-34,755
| -6% | -$130K | ﹤0.01% | 3673 |
|
|
2018
Q4 | $2.23M | Buy |
620,816
+142,159
| +30% | +$618K | ﹤0.01% | 3631 |
|
|
2018
Q3 | $2.74M | Buy |
478,657
+6,821
| +1% | +$39K | ﹤0.01% | 3667 |
|
|
2018
Q2 | $2.36M | Buy |
471,836
+6,030
| +1% | +$31K | ﹤0.01% | 3676 |
|
|
2018
Q1 | $2.39M | Sell |
465,806
-43,558
| -9% | -$262K | ﹤0.01% | 3635 |
|
|
2017
Q4 | $3.06M | Sell |
509,364
-61,416
| -11% | -$370K | ﹤0.01% | 3579 |
|
|
2017
Q3 | $3.17M | Buy |
570,780
+35,377
| +7% | +$183K | ﹤0.01% | 3594 |
|
|
2017
Q2 | $2.48M | Buy |
535,403
+19,258
| +4% | +$85.9K | ﹤0.01% | 3632 |
|
|
2017
Q1 | $2.56M | Buy |
+516,145
| New | +$4.97M | ﹤0.01% | 3588 |
|
|
2016
Q2 | – | Sell |
-1,567
| Closed | -$10K | – | 3865 |
|
|
2016
Q1 | $10K | Buy |
1,567
+995
| +174% | +$6.42K | ﹤0.01% | 3177 |
|
|
2015
Q4 | $5K | Hold |
572
| – | – | ﹤0.01% | 3179 |
|
|
2015
Q3 | $4K | Hold |
572
| – | – | ﹤0.01% | 3102 |
|
|
2015
Q2 | $6K | Buy |
+572
| New | +$6.32K | ﹤0.01% | 3097 |
|
BlackRock's FOMX Position: Q1 2020 in Review
BlackRock sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 564,004 shares — an estimated $1.88M sold.
BlackRock first reported a position in FOMX in Q2 2015 and held it in 16 quarters. The position peaked at $3.17M in Q3 2017. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- BlackRock reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- BlackRock sold 564,004 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $1.88M.
- BlackRock first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 16 quarters.
- BlackRock's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $3.17M in Q3 2017.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on BlackRock's 13F filing for Q1 2020, filed 1 May 2020.